



## **THOMSON MEDICAL GROUP LIMITED**

(Incorporated in the Republic of Singapore)  
(Company Registration No. 199908381D)

---

### **PROFIT GUIDANCE ON THE UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2024**

---

The Board of Directors of Thomson Medical Group Limited (the “**Company**” or “**TMG**”, together with its subsidiaries, the “**Group**”) wishes to announce that following a preliminary review of the unaudited financial results of the Group for the six months ended 31 December 2024 (“**1H2025**”), the Group is expected to record a loss after tax for the six months ended 31 December 2024 (“**1H2025**”).

The expected loss after tax for 1H2025 is primarily due to the poorer performance of the Malaysia market, partly resulting from the termination and discounts of certain insurance contracts, as well as increased interest expenses related to the acquisition of Far East Medical Vietnam Limited (“**FEMVN**”), along with the cessation of projects in Singapore.

The Company is in the process of finalising its unaudited financial results for 1H2025. Further details of the Group's financial performance will be disclosed when the Company announces its unaudited financial results for 1H2025 on or before 14 February 2025.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

**By Order of the Board**  
**THOMSON MEDICAL GROUP LIMITED**

Dr Heng Jun Li Melvin  
Executive Director and Group Chief Executive Officer  
24 January 2025